Long-term treatment of phenylketonuria with a new medical food containing large neutral amino acids

D. Concolino, I. Mascaro, M. T. Moricca, G. Bonapace, K. Matalon, J. Trapasso, Geetha Radhakrishnan, C. Ferrara, Reuben Matalon, P. Strisciuglio

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background/Objectives:Phenylketonuria (PKU) is an autosomal recessive disease caused by deficient activity of phenylalanine hydroxylase. A low phenylalanine (Phe) diet is used to treat PKU. The diet is very restrictive, and dietary adherence tends to decrease as patients get older. Methods to improve dietary adherence and blood Phe control are continuously under investigation.Subjects/Methods:A new formula Phe-neutral amino acid (PheLNAA) has been tested in this study with the purpose of improving the compliance and lowering blood phenylalanine. The formula has been tested for nitrogen balance, and it is nutritionally complete. It is fortified with more nutritional additives that can be deficient in the PKU diet, such as B12, Biotin, DHA, Lutein and increased levels of large neutral amino acids to help lower blood Phe. The new formula has been tested on 12 patients with a loading test of 4 weeks.Results:Fifty-eight percent of patients had a significant decline in blood Phe concentration from baseline throughout the study. The PheLNAA was well tolerated with excellent compliance and without illnesses during the study.Conclusions:In conclusion, the new formula is suitable for life-long treatment of PKU, and it offers the PKU clinic a new choice for treatment.

Original languageEnglish (US)
Pages (from-to)51-55
Number of pages5
JournalEuropean Journal of Clinical Nutrition
Volume71
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Neutral Amino Acids
Phenylketonurias
Phenylalanine
Food
Diet
Compliance
Therapeutics
Phenylalanine Hydroxylase
Lutein
Biotin
Nitrogen

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

Concolino, D., Mascaro, I., Moricca, M. T., Bonapace, G., Matalon, K., Trapasso, J., ... Strisciuglio, P. (2017). Long-term treatment of phenylketonuria with a new medical food containing large neutral amino acids. European Journal of Clinical Nutrition, 71(1), 51-55. https://doi.org/10.1038/ejcn.2016.166

Long-term treatment of phenylketonuria with a new medical food containing large neutral amino acids. / Concolino, D.; Mascaro, I.; Moricca, M. T.; Bonapace, G.; Matalon, K.; Trapasso, J.; Radhakrishnan, Geetha; Ferrara, C.; Matalon, Reuben; Strisciuglio, P.

In: European Journal of Clinical Nutrition, Vol. 71, No. 1, 01.01.2017, p. 51-55.

Research output: Contribution to journalArticle

Concolino, D, Mascaro, I, Moricca, MT, Bonapace, G, Matalon, K, Trapasso, J, Radhakrishnan, G, Ferrara, C, Matalon, R & Strisciuglio, P 2017, 'Long-term treatment of phenylketonuria with a new medical food containing large neutral amino acids', European Journal of Clinical Nutrition, vol. 71, no. 1, pp. 51-55. https://doi.org/10.1038/ejcn.2016.166
Concolino, D. ; Mascaro, I. ; Moricca, M. T. ; Bonapace, G. ; Matalon, K. ; Trapasso, J. ; Radhakrishnan, Geetha ; Ferrara, C. ; Matalon, Reuben ; Strisciuglio, P. / Long-term treatment of phenylketonuria with a new medical food containing large neutral amino acids. In: European Journal of Clinical Nutrition. 2017 ; Vol. 71, No. 1. pp. 51-55.
@article{9411b66985da4a88b3f36d96ef6f1e0c,
title = "Long-term treatment of phenylketonuria with a new medical food containing large neutral amino acids",
abstract = "Background/Objectives:Phenylketonuria (PKU) is an autosomal recessive disease caused by deficient activity of phenylalanine hydroxylase. A low phenylalanine (Phe) diet is used to treat PKU. The diet is very restrictive, and dietary adherence tends to decrease as patients get older. Methods to improve dietary adherence and blood Phe control are continuously under investigation.Subjects/Methods:A new formula Phe-neutral amino acid (PheLNAA) has been tested in this study with the purpose of improving the compliance and lowering blood phenylalanine. The formula has been tested for nitrogen balance, and it is nutritionally complete. It is fortified with more nutritional additives that can be deficient in the PKU diet, such as B12, Biotin, DHA, Lutein and increased levels of large neutral amino acids to help lower blood Phe. The new formula has been tested on 12 patients with a loading test of 4 weeks.Results:Fifty-eight percent of patients had a significant decline in blood Phe concentration from baseline throughout the study. The PheLNAA was well tolerated with excellent compliance and without illnesses during the study.Conclusions:In conclusion, the new formula is suitable for life-long treatment of PKU, and it offers the PKU clinic a new choice for treatment.",
author = "D. Concolino and I. Mascaro and Moricca, {M. T.} and G. Bonapace and K. Matalon and J. Trapasso and Geetha Radhakrishnan and C. Ferrara and Reuben Matalon and P. Strisciuglio",
year = "2017",
month = "1",
day = "1",
doi = "10.1038/ejcn.2016.166",
language = "English (US)",
volume = "71",
pages = "51--55",
journal = "European Journal of Clinical Nutrition",
issn = "0954-3007",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Long-term treatment of phenylketonuria with a new medical food containing large neutral amino acids

AU - Concolino, D.

AU - Mascaro, I.

AU - Moricca, M. T.

AU - Bonapace, G.

AU - Matalon, K.

AU - Trapasso, J.

AU - Radhakrishnan, Geetha

AU - Ferrara, C.

AU - Matalon, Reuben

AU - Strisciuglio, P.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background/Objectives:Phenylketonuria (PKU) is an autosomal recessive disease caused by deficient activity of phenylalanine hydroxylase. A low phenylalanine (Phe) diet is used to treat PKU. The diet is very restrictive, and dietary adherence tends to decrease as patients get older. Methods to improve dietary adherence and blood Phe control are continuously under investigation.Subjects/Methods:A new formula Phe-neutral amino acid (PheLNAA) has been tested in this study with the purpose of improving the compliance and lowering blood phenylalanine. The formula has been tested for nitrogen balance, and it is nutritionally complete. It is fortified with more nutritional additives that can be deficient in the PKU diet, such as B12, Biotin, DHA, Lutein and increased levels of large neutral amino acids to help lower blood Phe. The new formula has been tested on 12 patients with a loading test of 4 weeks.Results:Fifty-eight percent of patients had a significant decline in blood Phe concentration from baseline throughout the study. The PheLNAA was well tolerated with excellent compliance and without illnesses during the study.Conclusions:In conclusion, the new formula is suitable for life-long treatment of PKU, and it offers the PKU clinic a new choice for treatment.

AB - Background/Objectives:Phenylketonuria (PKU) is an autosomal recessive disease caused by deficient activity of phenylalanine hydroxylase. A low phenylalanine (Phe) diet is used to treat PKU. The diet is very restrictive, and dietary adherence tends to decrease as patients get older. Methods to improve dietary adherence and blood Phe control are continuously under investigation.Subjects/Methods:A new formula Phe-neutral amino acid (PheLNAA) has been tested in this study with the purpose of improving the compliance and lowering blood phenylalanine. The formula has been tested for nitrogen balance, and it is nutritionally complete. It is fortified with more nutritional additives that can be deficient in the PKU diet, such as B12, Biotin, DHA, Lutein and increased levels of large neutral amino acids to help lower blood Phe. The new formula has been tested on 12 patients with a loading test of 4 weeks.Results:Fifty-eight percent of patients had a significant decline in blood Phe concentration from baseline throughout the study. The PheLNAA was well tolerated with excellent compliance and without illnesses during the study.Conclusions:In conclusion, the new formula is suitable for life-long treatment of PKU, and it offers the PKU clinic a new choice for treatment.

UR - http://www.scopus.com/inward/record.url?scp=84987642742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987642742&partnerID=8YFLogxK

U2 - 10.1038/ejcn.2016.166

DO - 10.1038/ejcn.2016.166

M3 - Article

VL - 71

SP - 51

EP - 55

JO - European Journal of Clinical Nutrition

JF - European Journal of Clinical Nutrition

SN - 0954-3007

IS - 1

ER -